Elan, Biogen launch Tysabri trial in oncology
DUBLIN, Sept 5 (Reuters) - Biogen Idec (BIIB.O: Quote, Profile, Research, Stock Buzz) and Elan Corp (ELN.I: Quote, Profile, Research, Stock Buzz) have launched the first clinical trial of their multiple sclerosis drug Tysabri for patients with relapsed or refractory multiple myeloma, the companies said on Friday.
The first dose was administered on Thursday, they said.
Multiple myeloma is a cancer of the plasma cell. (Reporting by Jonathan Saul; Editing by Quentin Bryar)
© Thomson Reuters 2008 All rights reserved
Ads by Career Builder
Revenue Cycle Management/ Healthcare
Details: Growing Healthcare Consultancy organization seeks experienced Healthcare Revenue Cycle Management Consultancy talent (on...modeling, and labor productivity initiatives to healthcare providers and payers. INITIATIVES range from extensive...
Work from Home as a Healthcare Recruiter
Details: Work from Home as a Healthcare Recruiter Health Career Agents is an international healthcare recruiting and medical staffing company...Our organization represents high-demand healthcare professionals and works to secure the most desirable...
Regional Operations Director - Healthcare
Details: ...Director Regional Operations Director - Healthcare This position will be working out of...travel Good to have skills/experience: Healthcare Multi-Site Management experience What...provide exceptional benefits including the healthcare industry's most generous profit sharing...
Lawson Analyst - Payroll for healthcare
Details: ...Analyst with great experience within a healthcare industry environment, please read on...Medical Financial, Application Analyst, Healthcare Systems, Payroll, Oracle, Access...for the Lawson Analyst - Payroll for healthcare position, and have a background that...
Space beer lands in Japan
